Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Decreased by Candriam S.C.A.

Candriam S.C.A. cut its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 731,221 shares of the company's stock after selling 18,583 shares during the period. Candriam S.C.A. owned about 0.92% of Viridian Therapeutics worth $14,018,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of VRDN. R Squared Ltd acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Viridian Therapeutics in the 3rd quarter valued at about $149,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Viridian Therapeutics in the 3rd quarter valued at about $208,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Viridian Therapeutics by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after buying an additional 2,036 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Viridian Therapeutics by 19.5% in the 4th quarter. Arizona State Retirement System now owns 16,596 shares of the company's stock valued at $318,000 after buying an additional 2,708 shares during the period.

Analyst Ratings Changes

Several brokerages recently weighed in on VRDN. Royal Bank of Canada lifted their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. TD Cowen began coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Remove Ads

Viridian Therapeutics Price Performance

Shares of VRDN stock traded up $0.06 during midday trading on Friday, reaching $15.94. 1,008,783 shares of the company were exchanged, compared to its average volume of 1,184,738. Viridian Therapeutics, Inc. has a 12 month low of $11.40 and a 12 month high of $27.20. The company has a market cap of $1.26 billion, a P/E ratio of -3.70 and a beta of 1.05. The company's 50 day moving average price is $17.79 and its two-hundred day moving average price is $19.67. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.